rs397514580 — GCK GCK MODY2 E339K

GCK-MODY2 — The Glucose Sensor That's Set Too High

Glucokinase (GCK) is the pancreatic beta cell's glucose sensor — it detects rising blood sugar and triggers insulin release to bring it back down. In people with one functional copy of GCK, the sensor's threshold is permanently shifted upward, so the body defends a mildly elevated glucose set-point instead of a normal one. The result is lifelong, stable fasting hyperglycemia¹¹ lifelong, stable fasting hyperglycemia
Fasting glucose typically runs 5.4–8.3 mmol/L (97–150 mg/dL) and HbA1c 5.8–7.6%; levels are largely flat from birth through old age with minimal progression that almost never progresses to the vascular complications seen in type 2 diabetes.

The E339K variant (rs397514580) is a rare pathogenic missense change first identified in a Chinese MODY2 family. The glutamic acid at position 339 of the GCK protein is changed to lysine — a positively charged amino acid replacing a negatively charged one in a region critical for the protein's structural stability. This variant is classified as likely pathogenic by the ClinGen Monogenic Diabetes Expert Panel²² likely pathogenic by the ClinGen Monogenic Diabetes Expert Panel
ClinVar VCV000039759, reviewed February 2024, three-star expert panel status using the ClinGen GCK variant curation specifications.

The Mechanism

The GCK enzyme must bind glucose and then undergo a conformational change to catalyze the first step of glycolysis. Biochemical analysis of E339K³³ Biochemical analysis of E339K
Shen Y et al., Human Genetics 2011, PMID 21104275 demonstrated three converging defects: reduced protein yield, inactivated enzyme kinetics, and severely compromised thermal stability. The glutamate-to-lysine substitution (c.1015G>A on the coding strand, plus-strand genomic C>T) disrupts the structural integrity of the glucokinase protein, leading to a less functional and less stable enzyme that poorly responds to normal glucose concentrations. Because only one copy of the GCK gene is affected, the other functional allele still produces some active enzyme — enough to prevent severe diabetes, but not enough to restore normal glucose sensing.

The REVEL computational score for E339K is 0.963, exceeding the 0.70 threshold used as supporting evidence for pathogenicity. The mutation was absent in 200 healthy controls in the original Chinese family study and is essentially absent from gnomAD population databases (one observed allele in ~585,000), confirming it is not a common benign variant.

The Evidence

GCK-MODY (MODY2) as a class is well characterized⁴⁴ well characterized
Gaál Z et al. 2021, Life Basel, PMID 34440516 — accounting for up to 70% of confirmed MODY cases in some populations and affecting approximately 1 in 1,000 people globally. The E339K specific variant has been reported in a Chinese MODY2 pedigree where it co-segregated with diabetes and impaired glucose tolerance across five affected family members in two generations, with no unaffected family member carrying the mutation.

The cardinal clinical study for GCK-MODY management is Chakera et al. 2015 in Diabetes Care⁵⁵ Chakera et al. 2015 in Diabetes Care
Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation: despite 50+ years of elevated glucose, carriers show rates of microvascular complications comparable to the general non-diabetic population, and macrovascular disease risk also resembles the general population rather than diabetic cohorts. Glucose-lowering therapy is ineffective because it disrupts the body's reset set-point rather than correcting an underlying impairment in glucose handling.

The critical diagnostic problem: GCK-MODY is frequently misdiagnosed as type 1 or type 2 diabetes. Carriers who receive insulin or oral hypoglycemics gain no clinical benefit and are exposed to real harms including hypoglycemia from unnecessary treatment⁶⁶ hypoglycemia from unnecessary treatment
Glucose-lowering drugs drive glucose below the patient's genetically defended set-point without targeting the underlying cause; the MODY2 pancreas actively resists the treatment by reducing insulin secretion.

Practical Actions

The primary management goal is accurate diagnosis and avoidance of unnecessary treatment. Outside of pregnancy, no glucose-lowering medications are indicated. During pregnancy, management is nuanced: if the fetus has inherited the normal GCK allele, maternal glucose targets need tightening (the fetus's normal glucokinase will cause it to overproduce insulin and grow excessively on the elevated glucose); if the fetus also carries the mutation, standard maternal glucose targets apply and insulin treatment confers no benefit.

Interactions

GCK is the primary glucose sensor; its set-point interacts indirectly with insulin-secretion and insulin-sensitivity genes (e.g., TCF7L2, KCNJ11, ABCC8). Compound heterozygosity for two GCK inactivating variants is extremely rare but would produce a more severe phenotype approaching permanent neonatal diabetes rather than the mild MODY2 phenotype. Other MODY-causing genes in the same clinical category include HNF1A (MODY3) and HNF4A (MODY1) — differentiating these subtypes requires genetic testing because management differs substantially.